SIMCERE PHARMA (02096) spent 10.1667 million Hong Kong dollars to repurchase 1.49 million shares on November 18th.
Sinopharm (02096) announced that on November 18, 2024, the company invested 1016.67 million...
SIMCERE PHARMA (02096) announced that on November 18, 2024, the company repurchased 1.49 million shares at a cost of 10.167 million Hong Kong dollars. The repurchase price was between 6.71 and 6.98 Hong Kong dollars per share.
Related Articles
SSY GROUP (02005) has obtained the drug manufacturing registration approval from the National Medical Products Administration for Levofloxacin Drops (0.488% (5ml: 24.4mg)).
At the end of November, the net asset value per share of CN SCI-TECH IND (00339) was approximately 0.0307 Hong Kong dollars.
Innovative Practice from DEKON AGR (02419) on Teaching Farmers to Raise Sows, Balancing Profitability and Livelihoods.
SSY GROUP (02005) has obtained the drug manufacturing registration approval from the National Medical Products Administration for Levofloxacin Drops (0.488% (5ml: 24.4mg)).
At the end of November, the net asset value per share of CN SCI-TECH IND (00339) was approximately 0.0307 Hong Kong dollars.
Innovative Practice from DEKON AGR (02419) on Teaching Farmers to Raise Sows, Balancing Profitability and Livelihoods.
RECOMMEND
Baidu’s AI Ace Kunlunxin Prepares For Hong Kong IPO, Domestic Computing Power Faces Crucial Test
08/12/2025
Institutions Say Short-Term Volatility Does Not Alter Upward Trend Of Hong Kong Stocks, Hang Seng Index Still Expected To Challenge 30,000 Points Next Year
08/12/2025
As The 2025 Central Economic Work Conference Approaches, What New Expectations Lie Ahead For Next Year’s Economic Agenda? Institutions Forecast Five Key Highlights
08/12/2025
